Adagio presses forward with their FDA pitch for Covid antibody — despite Omicron flaws

Jason Mast

Editor

Adagio, the Tillman Gerngross biotech whose $750 million plan to build a pan-coronavirus antibody seemingly fell apart in the face of Omicron, is back …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adagio presses forward with their FDA pitch for Covid antibody — despite Omicron flaws

Jason Mast

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

Lilly pays $10M upfront for Organovo’s FXR agonist program

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Compounders sue FDA over removal of semaglutide from official shortage list

Repare to lay off 75% of staff; Castle Creek inks $75M royalty deal

How AI can address ongoing challenges in the life sciences industry

Ada­gio press­es for­ward with their FDA pitch for Covid an­ti­body — de­spite Omi­cron flaws

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Adagio presses forward with their FDA pitch for Covid antibody — despite Omicron flaws